Yiling Pharmaceutical Announces 2021 Revenue of $1.53 Billion


SHIJIAZHUANG, China, April 30, 2022 /PRNewswire/ — Yiling Pharmaceutical released its 2021 annual report on Friday and disclosed key development statistics. According to the report, its annual turnover reached $1.53 billionan increase of 15.19% over last year, in addition, net profit attributable to shareholders reached $203.75 millionachieving a growth of 10.27% year-on-year.

The annual sales of Tongxinluo capsules, Shensong Yangxin capsules and Qili Qiangxin capsules, Yiling’s top 3 products for cardio-cerebrovascular diseases, reached $687.4 million, accounting for 44.82% of overall revenue, achieving 31.56% year-on-year growth despite the Covid-19 hit. Notably, in 2021, the annual sales of Lianhua Qingwen Capsules reached $622.8 billion. It also ranked No. 1 in sales of patented traditional Chinese cold medicine in China public medical market in 2021H1, according to statistics.

Public information indicates that Lianhua Qingwen Capsules was developed during the SARS period, it is the only herbal cold and flu medicine that won the second prize in the China National Science and Technology Progress Award.

In 2020, a clinical study Efficacy and Safety of Repurposed Chinese Herb Lianhuaqingwen Capsules in Patients with Coronavirus Disease 2019: A Multicenter, Prospective, Randomized Controlled Trial Posted in Phytomedicineshows that with routine treatment, oral administration of Lianhua Qingwen Capsules for 14 days, clinical symptoms of COVID-19 such as fever, fatigue and cough can be significantly alleviated, and lung imaging lesions can be significantly improved, the duration of symptoms was obviously shortened, and the clinical cure rate was obviously high.

Lianhua Qingwen has been granted for sale in nearly 30 countries and regions. Additionally, it has been approved for COVID-19 indications in Kuwait and Mongoliaand selected to appear on the white list of anti-epidemic drugs published by the Ministry of Health of Uzbekistan. In July 2021it has been adopted as a treatment in the protocol for self-care of COVID-19 patients at home by the Cambodian Ministry of Health.

SOURCEYiling Pharmaceutical


Comments are closed.